Palliative Therapie von Gallengangs- und Gallenblasenkarzinomen

Zusammenfassung

Irresektable Gallengangs- und Gallenblasenkarzinome sind mit einer schlechten Prognose verbunden. Neben den Empfehlungen des „best supportive care” ist die Schaffung einer suffizienten biliären Drainage bei maligner Stenose der Gallenwege wichtiger Bestandteil der palliativen Therapie. Mit der photodynamischen Therapie steht mittlerweile ein Verfahren zur Verfügung, das in zwei Studien bei hilärem Gallengangskarzinom zu einem verbesserten Überleben geführt hat. Die externe Strahlentherapie und intraluminale Brachytherapie werden bisher nicht als gesichert wirksam gewertet. Auch die Indikation zur Chemotherapie ist weiterhin umstritten, lediglich eine einzige Studie mit einer kombinierten Gruppe an Patienten mit Gallenwegs- und Pankreaskarzinomen hat bisher einen Überlebensvorteil für diese Therapieform gezeigt. In den letzten Jahren wurden neue Protokolle mit vereinzelt viel versprechendem medianen Überleben angewendet. Lokale Wege der Chemotherapieapplikation sind bisher zu wenig evaluiert, um für diese Tumorart breit propagiert werden zu können. Lokal ablative Verfahren sind bisher nur in Einzelfällen eingesetzt worden. Eine weitere Evaluation dieser Therapiestrategien in klinischen Studien erscheint sinnvoll.

Abstract

Non-resectable cholangiocarcinoma and gallbladder carcinoma have a poor prognosis. In addition to the general aspects of “best supportive care”, biliary drainage is an important part of the palliative treatment of patients with malignant biliary stenosis. Photodynamic therapy has led to an improved median survival in hilar cholangiocarcinoma in two controlled studies. The survival benefit of external radiation or intraluminal brachytherapy has not yet been convincingly demonstrated. Whether or not systemic chemotherapy should be applied is still under debate. A single study including advanced biliary and pancreatic cancer patients has demonstrated a survival benefit for the combined group. In recent years, new chemotherapy protocols have been applied, some with promising results. Intra-arterial chemotherapy and chemotherapeutically coated stents have not been evaluated well enough to be recommended outside clinical studies. Ablative therapies have been used in a limited number of patients only. Further studies are necessary to clarify whether these treatment modalities are effective.

Cholangiozelluläres Karzinom - Gallenblasenkarzinom - Klatskin-Tumor - Gallengangskarzinom

Cholangiocellular carcinoma - gallbladder carcinoma - Klatskin’s tumour - cholangiocarcinoma

Literatur

• 1 Khan S A, Thomas H C, Davidson B R. et al . Cholangiocarcinoma.  Lancet. 2005;  366 1303-1314
• 2 Misra S, Chaturvedi A, Misra N C. et al . Carcinoma of the gallbladder.  Lancet Oncol. 2003;  4 167-176
• 3 Rea D J, Heimbach J K, Rosen C B. et al . Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.  Ann Surg. 2005;  242 451-458
• 4 Hertl M, Cosimi A B. Liver transplantation for malignancy.  Oncologist. 2005;  10 269-281
• 5 Shaib Y, El-Serag H B. The epidemiology of cholangiocarcinoma.  Semin Liver Dis. 2004;  24 115-125
• 6 Farley D R, Weaver A L, Nagorney D M. „Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention.  Mayo Clin Proc. 1995;  70 425-429
• 7 Chang W H, Kortan P, Haber G B. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage.  Gastrointest Endosc. 1998;  47 354-362
• 8 Berr F, Wiedmann M, Tannapfel A. et al . Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.  Hepatology. 2000;  31 291-298
• 9 Wiedmann M, Schoppmeyer K, Witzigmann H. et al . Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen.  Z Gastroenterol. 2005;  43 305-315
• 10 Khan S A, Davidson B R, Goldin R. et al . Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.  Gut. 2002;  51 (Suppl VI) vi1-vi9
• 11 Jakobs R, Weickert U, Hartmann D. et al . Interventionelle Endoskopie bei benignen und malignen Gallengangsstenosen.  Z Gastroenterol. 2005;  43 295-303
• 12 Kopf A, Bätjer N. Schmerztherapie in der gastroenterologischen Onkologie.  Z Gastroenterol. 2005;  43 1061-1069
• 13 Abraham N S, Barkun J S, Barkun A N. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life.  Gastrointest Endosc. 2002;  56 835-841
• 14 Prat F, Chapat O, Ducot B. et al . Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline.  Gut. 1998;  42 354-362
• 15 Deviere J, Baize M, de Toeuf J. et al . Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage.  Gastrointest Endosc. 1988;  34 95-101
• 16 De Palma G D, Galloro G, Siciliano S. et al . Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study.  Gastrointest Endosc. 2001;  53 547-553
• 17 Telford J J, Carr-Locke D L, Baron T H. et al . Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study.  Gastrointest Endosc. 2004;  60 916-920
• 18 Schiefke I, Zabel-Langhennig A, Wiedmann M. et al . Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer.  Gastrointest Endosc. 2003;  58 213-219
• 19 Bessoud B, de Baere T, Denys A. et al . Malignant gastroduodenal obstruction: palliation with self-expanding metallic stents.  J Vasc Interv Radiol. 2005;  16 247-253
• 20 Johnsson E, Thune A, Liedman B. Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation.  World J Surg. 2004;  28 812-817
• 21 Nuzzo G, Clemente G, Cadeddu F. et al . Palliation of unresectable periampullary neoplasms. „surgical” versus „non-surgical” approach.  Hepatogastroenterology. 2004;  51 1282-1285
• 22 McCaughan J S, Mertens B F, Cho C H. et al . Photodynamic therapy of non-resectable cholangiocarcinoma.  Arch Surg. 1991;  126 111-113
• 23 Ortner M AEJ, Liebetruth J, Schreiber S. et al . Photodynamic therapy of nonresectable cholangiocarcinoma.  Gastroenterology. 1998;  114 536-542
• 24 Harewood G C, Baron T H, Rumalla A. et al . Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma.  J Gastroenterol Hepatol. 2005;  20 415-420
• 25 Dumoulin F L, Gerhardt T, Fuchs S. et al . Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma.  Gastrointest Endosc. 2003;  57 860-867
• 26 Shim C S, Cheon Y K, Cha S W. et al . Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment.  Endoscopy. 2005;  37 425-433
• 27 Wiedmann M, Berr F, Schiefke I. et al . Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study.  Gastrointest Endosc. 2004;  60 68-75
• 28 Ortner M AEJ, Caca K, Berr F. et al . Successful photodynamic therapy for non-resectable cholangiocarcinoma: a randomised prospective study.  Gastroenterology. 2003;  125 1355-1363
• 29 Gores G J. A spotlight on cholangiocarcinoma.  Gastroenterology. 2003;  125 1536-1538
• 30 Wiedmann M, Caca K, Berr F. et al . Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma. A Phase II study.  Cancer. 2003;  97 2783-2790
• 31 Zoepf T, Jakobs R, Rosenbaum A. et al . Photodynamic therapy with 5-aminolaevulinic acid is not effective in bile duct cancer.  Gastrointest Endosc. 2001;  54 763-766
• 32 Zoepf T, Jakobs R, Arnold J C. et al . Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy.  Am J Gastroenterol. 2005;  100 2426-2430
• 33 Nanashima A, Yamaguchi H, Shibasaki S. et al . Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study.  J Gastroenterol. 2004;  39 1095-1101
• 34 Ohnishi H, Asada M, Shichijo Y. et al . External radiotherapy for biliary decompression of hilar cholangiocarcinoma.  Hepatogastroenterology. 1995;  42 265-268
• 35 Kocak Z, Ozkan H, Adli M. et al . Intraluminal brachytherapy with metallic stenting in the palliative treatment of malignant obstruction of the bile duct.  Radiat Med. 2005;  23 200-207
• 36 Montemaggi P, Costamagna G, Dobelbower R R. et al . Intraluminal brachytherapy in the treatment of pancreas and bile duct carcinoma.  Int J Radiat Oncol Biol Phys. 1995;  32 437-443
• 37 Mayer R, Stranzl H, Prettenhofer U. et al . Palliative treatment of unresectable bile duct tumours.  Acta Med Austriaca. 2003;  30 10-12
• 38 Nakayama H, Tsuji K, Matsui R. et al . External radiotherapy for decompression of cholangiocellular carcinoma with obstructive jaundice: report of a case.  Radiat Med. 2001;  19 297-301
• 39 Shinchi H, Takao S, Nishida H. et al . Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma.  J Surg Oncol. 2000;  75 89-94
• 40 Milella M, Salvetti M, Cerrotta A. et al . Interventional radiology and radiotherapy for inoperable cholangiocarcinoma of the extrahepatic bile ducts.  Tumori. 1998;  84 467-471
• 41 Lu J J, Bains Y S, Abdel-Wahab M. et al . High-dose-rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma.  Cancer J. 2002;  8 74-78
• 42 Tsujino K, Landry J C, Smith R G. et al . Definitive radiation therapy for extrahepatic bile duct carcinoma.  Radiology. 1995;  196 275-280
• 43 Takamura A, Saito H, Kamada T. et al . Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma.  Int J Radiat Oncol Biol. 2003;  57 1357-1365
• 44 Shin H S, Seong J, Kim W C. et al . Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts.  Int J Radiat Oncol Biol Phys. 2003;  57 105-112
• 45 Gonzalez Gonzalez D, Gouma D J, Rauws E A. et al . Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma.  Ann Oncol. 1999;  10 (Suppl 4) S215-S220
• 46 Fritz P, Brambs H J, Schraube P. et al . Combined external beam radiotherapy and intraluminal high dose rate brachytherapy on bile duct carcinomas.  Int J Radiat Oncol Biol Phys. 1994;  29 855-861
• 47 Kamada T, Saitou H, Takamura A. et al . The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy.  Int J Radiat Oncol Biol Phys. 1996;  34 767-774
• 48 Lameris J S, Stoker J, Nijs H G. et al . Malignant biliary obstruction: percutaneous use of self-expandable stents.  Radiology. 1991;  179 703-707
• 49 Shin H S, Seong J, Kim W C. et al . Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts.  Int J Radiat Oncol Biol Phys. 2003;  57 105-112
• 50 Bruha R, Petrtyl J, Kubecova M. et al . Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies - the question of long-term palliation.  Hepatogastroenterology. 2001;  48 631-637
• 51 Kuvshinoff B W, Armstrong J G, Fong Y. et al . Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy.  Br J Surg. 1995;  82 1522-1525
• 52 Eschelman D J, Shapiro M J, Bonn J. et al . Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined modality radiation therapy.  Radiology. 1996;  200 717-724
• 53 Ishii H, Furuse J, Nagase M. et al . Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting.  Hepatogastroenterology. 2004;  51 954-957
• 54 Bowling T E, Galbraith S M, Hatfield A R. et al . A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma.  Gut. 1996;  39 852-855
• 55 Launois B, Reding R, Lebeau G. et al . Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers.  J Hepatobiliary Pancreat Surg. 2000;  7 128-134
• 56 Foo M L, Gunderson L L, Bender C E. et al . External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma.  Int J Rad Oncol Biol Phys. 1997;  39 929-935
• 57 Morganti A G, Trodella L, Valentini V. et al . Combined modality treatment in unresectable extrahepatic biliary carcinoma.  Int J Radiat Oncol Biol Phys. 2000;  46 913-919
• 58 Deodato F, Clemente G, Mattiucci G C. et al . Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results.  Int J Radiat Oncol Biol Phys. 2006;  64 483-488
• 59 Matsumoto S, Kiyosue H, Komatsu E. et al . Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma.  Cancer. 2004;  100 2422-2429
• 60 Schleicher U M, Staatz G, Alzen G. et al . Combined external beam and intraluminal radiotherapy for irresectable Klatskin tumors.  Strahlenther Onkol. 2002;  178 682-687
• 61 Gebbia V, Majello E, Testa A. et al . Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-flourouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule.  Cancer. 1996;  78 1300-1307
• 62 Gelibter A, Malaguti P, Di Cosimo S. et al . Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.  Cancer. 2005;  104 1237-1245
• 63 Murad A M, Guimarães R C, Aragão B C. et al . Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.  Am J Clin Oncol. 2003;  26 151-154
• 64 Tsavaris N, Kosmas C, Gouveris P. et al . Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.  Invest New Drugs. 2004;  22 193-198
• 65 Park J S, Oh S Y, Kim S H. et al . Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.  Jpn J Clin Oncol. 2005;  35 68-73
• 66 Knox J J, Hedley D, Oza A. et al . Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.  J Clin Oncol. 2005;  23 2332-2338
• 67 Glimelius B, Hoffman K, Sjoden P O. et al . Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.  Ann Oncol. 1996;  7 593-600
• 68 Taïeb J, Mitry E, Boige V. et al . Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.  Ann Oncol. 2002;  13 1192-1196
• 69 Knox J J, Hedley D, Oza A. et al . Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.  Ann Oncol. 2004;  15 770-774
• 70 Kubicka S, Rudolph K L, Tietze M K. et al . Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.  Hepatogastroenterology. 2001;  48 783-789
• 71 Ducreux M, Van Cutsem E, Van Laethem J L. et al . A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40 955 EORTC trial.  Eur J Cancer. 2005;  41 398-403
• 72 Falkson G, MacIntyre J M, Moertel C G. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer.  Cancer. 1984;  54 965-969
• 73 Choi C W, Choi I K, Seo J H. et al . Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.  Am J Clin Oncol. 2000;  23 425-428
• 74 Chen J S, Jan Y Y, Lin Y C. et al . Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.  Anticancer Drugs. 1998;  9 393-397
• 75 Raderer M, Hejna M HL, Valencak J B. et al . Two consecutive phase II studies of 5-flourouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.  Oncol. 1999;  56 177-180
• 76 Von Delius S, Lersch C, Schulte-Frohlinde E. et al . Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.  BMC Cancer. 2005;  5 61
• 77 Eng C, Ramathan R K, Wong M K. et al . A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.  Am J Clin Oncol. 2004;  27 565-569
• 78 Penz M, Kornek G V, Raderer M. et al . Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.  Ann Oncol. 2001;  12 183-186
• 79 Gallardo J O, Rubio B, Fodor M. et al . A phase II study of gemcitabine in gallbladder carcinoma.  Ann Oncol. 2001;  12 1403-1406
• 80 Gebbia V, Giuliani F, Maiello E. et al . Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.  J Clin Oncol. 2001;  19 4089-4091
• 81 Mezger J, Sauerbruch T, Ko Y. et al . Phase II study with gemcitabine in gallbladder and biliary tract carcinomas.  Onkologie. 1998;  21 232-234
• 82 Valencak J, Kornek G V, Raderer M. et al . Gemcitabine for the treatment of advanced biliary tract carcinomas: evaluation of two different dose regimens.  Onkologie. 1999;  22 498-501
• 83 Okada S, Ishii H, Nose H. et al . A phase II study of cisplatin in patients with biliary tract carcinoma.  Oncology. 1994;  51 515-517
• 84 Taal B G, Audisio R A, Bleiberg H. et al . Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study.  Ann Oncol. 1993;  4 607-609
• 85 Von Eyben F, Hellekant C, Mattsson W. et al . Mitomycin C in advanced gallbladder carcinoma.  Acta Radiol Oncol. 1980;  19 81-84
• 86 Jones D V, Lozano R, Hoque A. et al . Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas.  J Clin Oncol. 1996;  14 2306-2310
• 87 Sanz-Altamira P M, O’Reilly E, Stuart K E. et al . A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.  Ann Oncol. 2001;  12 501-504
• 88 Alberts S R, Fishkin P A, Burgart L J. et al . CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.  Int J Gastrointest Cancer. 2002;  32 107-114
• 89 Abou-Alfa G K, Rowinsky E K, Patt Y Z. et al . A phase II study of intravenous exatecan administered daily for 5 days, every 4 weeks to patients with biliary tract cancers.  Am J Clin Oncol. 2005;  28 334-339
• 90 Papakostas P, Kouroussis C, Androulakis N. et al . First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.  Eur J Cancer. 2001;  37 1833-1838
• 91 Pazdur R, Royce M E, Rodriguez G I. et al . Phase II trial of docetaxel for cholangiocarcinoma.  Am J Clin Oncol. 1999;  22 78-81
• 92 Chen J S, Yang T S, Lin Y C. et al . A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas.  Jpn J Clin Oncol. 2003;  33 353-356
• 93 Mani S, Sciortino D, Samules B. et al . Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.  Invest New Drugs. 1999;  17 97-101
• 94 Ikeda M, Okusaka T, Ueno H. et al . A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.  Jpn J Clin Oncol. 2005;  35 439-443
• 95 Patt Y Z, Hassan M M, Aguayo A. et al . Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.  Cancer. 2004;  101 578-586
• 96 Ueno H, Okusaka T, Ikeda M. et al . Phase II study of S-1 in patients with advanced biliary tract cancer.  Br J Cancer. 2004;  91 1769-1774
• 97 Takada T, Kato H, Matsushiro T. et al . Comparison of 5-fluorouracil, doxorubicin, and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas.  Oncology. 1994;  51 396-400
• 98 Sanz-Altamira P M, Ferrante K, Jenkins R L. et al . A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.  Cancer. 1998;  82 2321-2325
• 99 Chen J S, Lin Y C, Jan Y Y. et al . Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.  Anti-Cancer Drugs. 2001;  12 339-343
• 100 Ducreux M, Rougier P, Fandi A. et al . Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.  Ann Oncol. 1998;  9 653-656
• 101 Nehls O, Klump B, Arkenau H T. et al . Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.  Br J Cancer. 2002;  87 702-704
• 102 Boxberger F, Jüngert B, Brueckl V. et al . Palliative chemotherapy with gemcitabine and weekly high-dose 5-flourouracil as 24-h infusion in metastatic biliary tract and gall bladder carcinoma.  Anti-Cancer Drugs. 2003;  14 87-90
• 103 Hsu C, Shen Y C, Yang C H. et al . Weekly gemcitabine plus 24-h infusion of high-dose 5-flourouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.  Br J Cancer. 2004;  90 1715-1719
• 104 Alberts S R, Al-Khatib H, Mahoney M R. et al . Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma.  Cancer. 2005;  103 111-118
• 105 André T, Tournigand C, Rosmorduc O. et al . Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.  Ann Oncol. 2004;  15 1339-1343
• 106 Kuhn R, Hribaschek A, Eichelmann K. et al . Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.  Invest New Drugs. 2002;  20 351-356
• 107 Thongprasert S, Napapan S, Charoentum C. et al . Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.  Ann Oncol. 2005;  16 279-281
• 108 Kornek G V, Schuell B, Laengle F. et al . Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.  Ann Oncol. 2004;  15 478-483
• 109 Bhargava P, Jani C R, Savarese D M. et al . Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.  Oncology (Williston Park). 2003;  17 (Suppl 8) 23-26
• 110 Cho J Y, Paik Y H, Chang Y S. et al . Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.  Cancer. 2005;  104 2753-2758
• 111 Malik I A, Aziz Z, Zaidi S H. et al . Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.  Am J Clin Oncol. 2003;  26 174-177
• 112 Doval D C, Sekhon J S, Gupta S K. et al . A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.  Br J Cancer. 2004;  90 1516-1520
• 113 Kim T W, Chang H M, Kang H J. et al . Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.  Ann Oncol. 2003;  14 1115-1120
• 114 Patt Y Z, Hassan M M, Lozano R D. et al . Phase II trial of cisplatin, interferon a-2b, doxorubicin, and 5-flourouracil for biliary tract cancer.  Clin Cancer Res. 2001;  7 3375-3380
• 115 Patt Y Z, Jones D V, Hoque A. et al . Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.  J Clin Oncol. 1996;  14 2311-2315
• 116 Kajanti M, Pyrhonen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.  Am J Clin Oncol. 1994;  17 223-226
• 117 Ellis P A, Norman A, Hill A. et al . Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.  Eur J Cancer. 1995;  31A 1594-1598
• 118 Lee M A, Woo I S, Kang J H. et al . Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.  J Cancer Res Clin Oncol. 2004;  130 346-350
• 119 Park S H, Park Y H, Lee J N. et al . Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.  Cancer. 2006;  106 361-365
• 120 Park K H, Choi I K, Kim S J. et al . The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.  Cancer. 2005;  103 2338-2343
• 121 Harvey J H, Smith F P, Schein P S. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.  J Clin Oncol. 1984;  2 1245-1248
• 122 Cho J Y, Nam J S, Park M S. et al . A phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.  Yonsei Med J. 2005;  46 526-531
• 123 Wu T. Cyclooxygenase-2 and prostaglandin signalling in cholangiocarcinoma.  Biochim Biophys Acta. 2005;  1755 135-150
• 124 Reichle A, Klebl F, Bross K. et al .Pioglitazone and rofecoxib combined with angiostatically scheduled capecitabine in far-advanced hepatobiliary carcinoma. Proceedings of the 3rd International Conference on Tumor Microenvironment. Prague/Czech Republic; October 12 - 16 2004: 87-97
• 125 Sali A, McQuillan T, Read A. et al . Rifampicin as cytotoxic agent for cholangiocarcinoma: preliminary report of seven cases.  J Cancer Res Clin Oncol. 1991;  117 503-504
• 126 Makela J T, Kairaluoma M I. Superselective intra-arterial chemotherapy with mitomycin for gallbladder cancer.  Br J Surg. 1993;  80 912-915
• 127 Tanaka N, Yamakado K, Nakatsuka A. et al . Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma - initial experience.  Eur J Radiol. 2002;  41 42-48
• 128 Cantore M, Mambrini A, Fiorentini G. et al . Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.  Cancer. 2005;  103 1402-1407
• 129 Melichar B, Cerman J, Dvorak J. et al . Regional chemotherapy in biliary tract cancers - a single institution experience.  Hepatogastroenterology. 2002;  49 900-906
• 130 Smith G W, Bukowski R M, Hewlett J S. et al . Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma.  Cancer. 1984;  54 1513-1516
• 131 Mezawa S, Homma H, Sato T. et al . A study of carboplatin-coated tube for the unresectable cholangiocarcinoma.  Hepatology. 2000;  32 916-923
• 132 Burger I, Hong K, Schulick R. et al . Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution.  J Vasc Interv Radiol. 2005;  16 353-361
• 133 Berber E, Ari E, Herceg N. et al . Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes.  Surg Endosc. 2005;  19 1613-1617
• 134 Kirchhoff T, Zender L, Merkesdal S. et al . Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver.  World J Gastroenterol. 2005;  11 1091-1095
• 135 Gaffke G, Gebauer B, Knollmann F D. et al . Use of semiflexible applicators for radiofrequency ablation of liver tumors.  Cardiovasc Intervent Radiol. 2006;  29 270-275
• 136 Shiozawa K, Ishii K, Mori T. et al . Heterochronous development of intrahepatic cholangiocellular carcinoma following hepatocellular carinoma in a hepatits B virus carrier.  Intern Med. 2001;  40 624-630
• 137 Zuber-Jerger I, Blum H E. Chologener Abszess nach lokaler Thermoablation eines cholangiozellulären Karzinoms.  Dtsch Med Wochenschr. 2003;  128 2300-2302
• 138 Sheen A J, Poston G J, Sherlock D J. Cryotherapeutic ablation of liver tumours.  Br J Surg. 2002;  89 1396-1401